Source - LSE Regulatory
RNS Number : 0099P
Hikma Pharmaceuticals Plc
15 June 2022
 

Hikma Pharmaceuticals PLC - Company Secretary Change

 

 

London, 15 June 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces that Peter Speirs will step down as Company Secretary and Hussein Arkhagha, Chief Counsel, will take on the additional role as Company Secretary effective from 15 June 2022.

 

 

 

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

                                                           

Susan Ringdal, EVP Strategy and Global Affairs                                                             +44 (0)20 7399 2760

 


About Hikma

 

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

 

 

(LEI:549300BNS685UXH4JI75)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
COSFLFEFRSIELIF
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.